<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077983</url>
  </required_header>
  <id_info>
    <org_study_id>ICC-afterresection</org_study_id>
    <nct_id>NCT04077983</nct_id>
  </id_info>
  <brief_title>Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma</brief_title>
  <official_title>a Single-arm Study of Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase 2 study, we aim to evaluate the effects and safety of combined therapy using&#xD;
      nab-paclitaxel and gemcitabine chemotherapy for patients after radical resection of&#xD;
      Intrahepatic Cholangiocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most patients with intrahepatic cholangiocarcinoma (ICC) are often accompanied by local or&#xD;
      distant metastases and lose the opportunity for surgical resection. Surgical resection is the&#xD;
      only effective means for long-term survival of patients with intrahepatic cholangiocarcinoma.&#xD;
      However, multiple tumors, lymph node metastasis, and vascular invasion significantly reduced&#xD;
      postoperative survival. Most patients will relapse due to less clinical data. The best&#xD;
      adjuvant treatment strategy and standard protocol for patients with intrahepatic&#xD;
      cholangiocarcinoma has not been determined. Current treatment options include chemotherapy&#xD;
      based on fluoropyrimidine or gemcitabine. Albumin-bound paclitaxel(nab-paclitaxel) has been&#xD;
      used to treat a variety of malignancies such as non-small cell lung cancer, pancreatic&#xD;
      cancer, breast cancer, melanoma, ovarian cancer and the like. In the field of pancreatic&#xD;
      cancer, studies have confirmed that albumin-bound paclitaxel has synergistic effects with&#xD;
      gemcitabine. The combination of gemcitabine alone significantly increased the intratumoral&#xD;
      concentration of gemcitabine. Albumin-bound paclitaxel plus gemcitabine is the first choice&#xD;
      for first-line treatment of pancreatic cancer, but clinical studies in the field of&#xD;
      cholangiocarcinoma are very limited. Based on the same origin of pancreatic and biliary&#xD;
      embryos, biological behavior and pathological similarities. Therefore, in this second phase&#xD;
      of the study, our aim was to evaluate the efficacy and safety of chemotherapy with&#xD;
      nab-paclitaxel and gemcitabine in the prevention of postoperative recurrence in patients with&#xD;
      intrahepatic cholangiocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>the time from the day after surgery to the recurrence of cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety: the potential side effects</measure>
    <time_frame>6 months</time_frame>
    <description>the potential side effects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>the time from the day after surgery to death</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cholangiocarcinoma, Intrahepatic</condition>
  <arm_group>
    <arm_group_label>combined therapy using nab-paclitaxel and gemcitabine chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2&#xD;
Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2&#xD;
Three weeks is a course of treatment with a total of 4 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined therapy using nab-paclitaxel and gemcitabine chemotherapy</intervention_name>
    <description>Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2&#xD;
Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2&#xD;
Three weeks is a course of treatment with a total of 4 courses.</description>
    <arm_group_label>combined therapy using nab-paclitaxel and gemcitabine chemo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must have good compliance, be understood the research process of this&#xD;
             study and required to sign an informed consent form;&#xD;
&#xD;
          2. age 18-75 years old, male or female;&#xD;
&#xD;
          3. Histopathologically confirmed intrahepatic cholangiocarcinoma，excluding mixed liver&#xD;
             cancer;&#xD;
&#xD;
          4. The longest diameter of a single tumor in patients before surgery is 3~9cm. If the&#xD;
             number of multiple tumors is ≤3, the total diameter≤9cm, maximum diameter ≤5cm;&#xD;
&#xD;
          5. Study treatment can be started within 4~6 weeks after R0 resection;&#xD;
&#xD;
          6. Except for R0 resection, no other anti-tumor treatment has been received;&#xD;
&#xD;
          7. No distant transfer；&#xD;
&#xD;
          8. ECOG&lt;2, or KPS&gt;70；&#xD;
&#xD;
          9. Bone marrow function criteria: hemoglobin (HGB)≥90g/L; absolute neutrophil count&#xD;
             (ANC)≥1.5×109/L; platelets (PLT)≥100×109/L;&#xD;
&#xD;
         10. Liver function criteria: ALT, AST≤5×ULN, serum total bilirubin&lt;3×ULN;&#xD;
&#xD;
         11. Renal function criteria: creatinine clearance &gt; 45 mL/min&#xD;
&#xD;
         12. Prothrombin time &lt;14s; (no anticoagulant therapy);&#xD;
&#xD;
         13. Patients without biliary obstruction who require biliary stent implantation must be&#xD;
             completed at least 7 days prior to enrollment;&#xD;
&#xD;
         14. Non-lactating or pregnant women, contraception during or after 6 months of treatment.&#xD;
&#xD;
         15. No contraindications for gemcitabine and Nab-paclitaxel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those patients who are allergic to the chemotherapy drugs and their components in this&#xD;
             study&#xD;
&#xD;
          2. Patients with other malignant tumors within 5 years (except for cured carcinoma in&#xD;
             situ or basal cell carcinoma of the skin)&#xD;
&#xD;
          3. Concomitant diseases that may interfere with treatment studies: such as severe&#xD;
             infections, HIV-positive, clinically severe (ie active) Heart disease, uncontrolled&#xD;
             epilepsy, central nervous system disease, or history of mental disorders;&#xD;
&#xD;
          4. Intraoperative or postoperative pathology determines patients who do not meet radical&#xD;
             resection;&#xD;
&#xD;
          5. Patients with current or previous ≥ grade II peripheral neuropathy;&#xD;
&#xD;
          6. Patients who participated in other clinical studies within 4 weeks prior to&#xD;
             enrollment;&#xD;
&#xD;
          7. Patients who has undergone organ transplantation;&#xD;
&#xD;
          8. Patients considered by the investigator not suitable for this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhou, MD&amp;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>qi-man sun, MD</last_name>
    <phone>+8618616882028</phone>
    <email>sun.qiman@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guo-Ming Shi, MD</last_name>
    <phone>+8613916969578</phone>
    <email>shi.guoming@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006 Feb 15;12(4):1317-24. Erratum in: Clin Cancer Res. 2006 Jun 15;12(12):3869. Dosage error in article text.</citation>
    <PMID>16489089</PMID>
  </reference>
  <reference>
    <citation>Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012 Mar;2(3):260-269. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.</citation>
    <PMID>22585996</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.</citation>
    <PMID>21969517</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 1, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrahepatic cholangiocarcinoma</keyword>
  <keyword>nab-paclitaxel and gemcitabine chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

